Skip to main content

Table 2 Subgroup analyses for the effect on the blood glucose

From: Association between ICS use and risk of hyperglycemia in COPD patients: systematic review and meta-analysis

Subgroup title No of trials No of participants Risk ratio (95% CI) P Value I2 (%)
Overall 6 8216 1.20 (0.79–1.82) 0.40 0
Daily dose      
 Low dose 2 1949 1.20 (0.66–2.20) 0.53 22.3
 Medium dose 2 4170 1.19 (0.72–1.95) 0.50 28.3
 High dose 2 2097 1.38 (0.80–2.40) 0.25 0
Duration      
 Less than 24 weeks 1 1620 1.01(0.29–3.48) 0.99  
 At least 24 weeks 5 6596 1.22 (0.78–1.91) 0.37 30.3